David LaVance Named Partner In Fervent Pharmaceuticals

David LaVance, formerly a strategic advisor to Fervent Pharmaceuticals, has become a partner in the company. Mr. LaVance is a businessman with extensive experience in strategic planning for biotechnology and medical device companies, technology licensing, and international distribution. He will join CEO George Royster and the rest of the Fervent team in continuing to make their innovative menopause treatment a reality.

Mr. LaVance initially joined Fervent in the spring of last year as a strategic advisor, working closely with Mr. Royster to develop business, patent, and funding strategies for Fervent. His contributions were invaluable, and both he and Mr. Royster became eager for him to take on an even more substantial role at the company.

Mr. LaVance is the former Chairman of the Board of Hologic, Inc., a medical device and diagnostics company headquartered in Boston (HOLX). He is also the Chairman and CEO of Integrated Environmental Technologies, Ltd. (IEVM), a public company specializing in providing disinfectants and biocides to industry. He is the CEO of Scivanta Medical Corporation (SCVM), a publicly-traded medical device company focused on development of the Scivanta Cardiac Monitoring System.

Fervent’s founder and CEO is excited about the new partner. “David is already a crucial member of our team,” Mr. Royster said. “His vast experience in developing life science companies has been indispensable, and I’m happy to welcome him aboard as Fervent’s newest partner.”